The Bristol based cloud robotics specialist raised the capital from backers including Legal & General Capital and Equinor Ventures to support its global growth plans.
"We’re delighted to have gained the support of some of the industry’s leading businesses and investors to help us execute on our vision – to change the way we conduct over the horizon robotic operations. In doing so, we will not only help the marine industries become safer and more profitable, but will make the investment case for the energy transition more attractive, accelerating the journey to net zero."
DWS joins an investor syndicate led by Chrysalis Investments to back the retirement technology provider.
"We are looking forward to delivering on the opportunity to work with an innovative retiretech disruptor that is fast-growing and well-placed to compete both in the UK and global retirement market. Increasingly, defined contribution savers are seeking to diversify their returns across a broader range of asset classes, and we believe that DWS’ asset management capabilities across both private and listed markets means that we are ideally placed to meet their evolving needs"
— Dirk Goergen, Member of the Executive Board and Head of Client Coverage Division
The financing round drew participation from Legal & General, Tencent, and QVentures to support genomics software development.
"We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates and we believe David and his team are doing just that. We are pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey."
The financing round was co-led by Tencent and Legal & General to support international expansion and product development.
"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."
